These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 16301833

  • 1. Managing patients treated with bevacizumab combination therapy.
    Gordon MS, Cunningham D.
    Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
    [Abstract] [Full Text] [Related]

  • 2. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
    Hurwitz H, Saini S.
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
    [Abstract] [Full Text] [Related]

  • 3. [Anti-angiogenic treatment and colorectal cancer].
    André T, Tournigand C, Abbas F, Louvet C, de Gramont A, Gercor (French Oncology Research Group).
    Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
    [Abstract] [Full Text] [Related]

  • 4. Managing patients with metastatic colorectal cancer on bevacizumab.
    Lemmens L, Claes V, Uzzell M.
    Br J Nurs; 2007 Jul; 17(15):944-9. PubMed ID: 18983014
    [Abstract] [Full Text] [Related]

  • 5. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S, Komatsu Y, Yuki S, Kusumi T, Hatanaka K, Nakamura M, Kato T, Miyagishima T, Hosokawa A, Iwanaga I, Sakata Y, Asaka M.
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [Abstract] [Full Text] [Related]

  • 6. Safety of bevacizumab in patients with metastatic breast cancer.
    Hamilton EP, Blackwell KL.
    Oncology; 2011 Apr; 80(5-6):314-25. PubMed ID: 21778772
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T, Lindley C.
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [Abstract] [Full Text] [Related]

  • 9. Intricacies of bevacizumab-induced toxicities and their management.
    Gressett SM, Shah SR.
    Ann Pharmacother; 2009 Mar; 43(3):490-501. PubMed ID: 19261963
    [Abstract] [Full Text] [Related]

  • 10. Managing adverse events in the use of bevacizumab and chemotherapy.
    Blowers E, Hall K.
    Br J Nurs; 2009 Mar; 18(6):351-6, 358. PubMed ID: 19329899
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
    Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H.
    J Surg Oncol; 2005 Sep 01; 91(3):173-80. PubMed ID: 16118771
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bevacizumab safety in Japanese patients with colorectal cancer.
    Hatake K, Doi T, Uetake H, Takahashi Y, Ishihara Y, Shirao K.
    Jpn J Clin Oncol; 2016 Mar 01; 46(3):234-40. PubMed ID: 26774113
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.